RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
RVL Pharmaceuticals has reported continued commercial momentum for its lead product, Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, with third-quarter 2025 revenue up 22% compared to the same period in 2024. The company expects further acceleration in the fourth quarter.
Upneeq is the first and only FDA-approved prescription eye drop for acquired ptosis (low-lying eyelids) in adults. The product’s growth is being driven by broader adoption, expanded distribution channels, and high patient satisfaction, according to RVL.
“Recent commercial investments have driven a clear inflection, with Upneeq Q3 2025 revenue up 22% versus Q3 2024, and further quarter-over-quarter acceleration expected in Q4 2025. These results underscore the strength of the Upneeq brand and the continued effectiveness of our commercial strategy,” said Katerina Gembarski, Chief Financial Officer.
To support this growth, RVL has appointed Lori Deo as Chief Executive Officer and Amy Shah as Chief Growth Officer. Deo previously served as Executive Chairwoman of the Board and has held senior roles at Johnson & Johnson and Pfizer. Shah also brings experience from Johnson & Johnson and will lead an integrated commercial organization overseeing sales, marketing, and pipeline development.
“RVL is entering a pivotal next phase of growth,” said Deo. “We are committed to investing with intention to unlock TAM, build and scale a new category, and accelerate brand and platform momentum.”
Photo: ID 597185 © Gvictoria | Dreamstime.com
